Colossal Biosciences was valued at approximately $10.2 billion following a $200M Series C in January 2025. In July 2026, the company was reportedly in discussions to raise new capital at a valuation of at least $20 billion.

Founded in 2021, Colossal raised early capital from investors including Breyer Capital, Draper Associates, and ARCH Venture Partners. It completed a Series B before closing the $200M Series C, bringing cumulative funding to $435M. In September 2025, Colossal raised a $120M extension tied to its dodo de-extinction program. In February 2026, it closed a $60M investment from the Government of the United Arab Emirates as part of its BioVault expansion.

Investors across rounds include TWG Global, U.S. Innovative Technology Fund, Robert Nelsen and ARCH Venture Partners, Peter Jackson, In-Q-Tel, Breyer Capital, Draper Associates, and PEAK6. Total capital raised by the for-profit entity reached approximately $615M by March 2026. The Colossal Foundation, a separate nonprofit, had secured $100M in funding by December 2025.

Colossal Biosciences uses CRISPR gene editing, cloning, stem-cell reprogramming, and biobanking to functionally recreate extinct species and protect endangered ones. Its six de-extinction programs cover the woolly mammoth, thylacine, dodo, dire wolf, moa, and bluebuck, with each serving as a development program for a reusable technology stack applicable to living wildlife.

The workflow starts with recovering and digitally reconstructing ancient genomes from museum specimens, fossils, or preserved tissue. Computational teams align millions of short, damaged DNA fragments against genomes from living relatives to identify genetic differences associated with traits such as hair density, fat metabolism, cold tolerance, or body size. Scientists use CRISPR to install selected edits into cells from a living relative, validate the changes through sequencing and tissue differentiation, and attempt to produce embryos through somatic-cell nuclear transfer or germ-cell engineering, depending on the animal class.

For mammals such as the mammoth, an edited nucleus is placed into an enucleated egg and transferred to a surrogate, in this case, an Asian elephant. Because conventional cloning does not work for birds such as the dodo, Colossal edits primordial germ cells and places them into host birds whose offspring carry the engineered reproductive cells. The company has also developed a 3D-printed artificial eggshell system that successfully hatched 26 chickens in 2026, creating a potential incubation path for the dodo and the much larger moa.

The dire-wolf program has produced three engineered canids, Romulus, Remus, and Khaleesi. Born via domestic-dog surrogates, the animals carry 20 edits across 14 loci in gray-wolf-derived cells. They are engineered proxies rather than genetic copies of ancient dire wolves, a distinction that has generated scientific interest and debate about what constitutes de-extinction.

Through ViaGen, Colossal offers cloning services for pets and horses. Owners preserve a tissue sample and cell line, after which ViaGen creates embryos from the stored cells, transfers them to surrogates, and delivers a genetically matched animal. BioVault, the company's biodiversity infrastructure product, collects, sequences, cryopreserves, and catalogs biological material from endangered species. Its Dallas repository holds materials from roughly 200 species, with a planned global network targeting 10,000 species.

Colossal Biosciences uses a vertically integrated deep-technology model, funding foundational R&D with venture capital and monetizing the resulting capabilities through commercial subsidiaries, government partnerships, and spinout equity. The for-profit company develops core technologies and owns relevant IP, while the nonprofit Colossal Foundation deploys selected tools in field conservation projects where customers cannot pay commercial rates.

The company sells through three channels. ViaGen offers high-ticket, low-volume consumer and commercial services: dog and cat cloning at $50,000, horse cloning at $85,000, and genetic preservation at roughly $1,600 with recurring annual storage fees. Government and institutional partnerships, including the UAE BioVault deal and the U.S. Fish and Wildlife Service biobanking initiative, generate large contract values for laboratory infrastructure, sample processing, sequencing, and species-recovery services. Technology spinouts, including Form Bio for computational biology and Breaking for plastic-degrading enzymes, allow Colossal to retain equity in standalone ventures serving pharmaceutical, industrial, or research customers without building each downstream sales organization.

The cost structure is capital intensive. Expenses include specialized scientific labor, laboratory construction, sequencing and computation, reagents, animal facilities, surrogate management, failed embryo attempts, cryogenic storage, and international field logistics. Unlike software, wet-lab and animal-development work does not scale at near-zero marginal cost. Margin profiles vary by output: licensed IP and software can carry high gross margins, cell banking generates recurring storage revenue, and spinout equity can create value without ongoing parent-level delivery costs.

The model uses high-profile extinct species to attract capital and fund platform development. Mammoths, dodos, and dire wolves draw more public attention than a project framed around improving non-model-species cell culture. That attention helps recruit scientists, attract private capital, form government partnerships, and make technical milestones legible to a broad audience. The resulting funding supports additional platform capabilities that can be applied to living endangered species or commercialized through adjacent ventures.

Colossal Biosciences has no direct commercial rival with comparable financing, species breadth, and an integrated de-extinction platform. Competition instead comes from genetic-rescue nonprofits, institutional biobanks, academic reproductive programs, and gene-editing companies competing for talent, specimens, funding, and institutional credibility.

Revive & Restore is the closest mission-level competitor, operating as a nonprofit funder and coordinator across conservation cloning, gene editing, and reproductive technology for species including black-footed ferrets, Przewalski's horses, and passenger pigeons. Its advantages include more than a decade of relationships with wildlife agencies, zoos, and academic laboratories, as well as a distributed R&D model that avoids the fixed costs of a large internal organization.

Revive & Restore is a competitor in government and conservation procurement, where peer-reviewed evidence and agency relationships can outweigh development speed and public attention. The organizations can also be partners, but they compete indirectly for donors, specimens, researchers, and control of the genetic-rescue narrative.

The San Diego Zoo Wildlife Alliance Frozen Zoo holds living cells and reproductive material from approximately 1,300 species accumulated over 50 years, making it the largest biological-asset incumbent by disclosed species count. In February 2026, it partnered with Illumina to sequence up to 4,000 individual samples, creating an alternative sequencing and biobanking stack without Colossal.

Colossal's BioVault targets a global network and includes a partnership with U.S. Fish and Wildlife Service to biobank every species protected under the Endangered Species Act. The UK-based Nature's SAFE occupies a similar niche through European zoo and veterinary networks. Established biobanks could form their own sequencing and reproductive partnerships, limiting Colossal's access to scarce samples.

Mammoth Biosciences, Arbor Biotechnologies, Beam Therapeutics, and Tessera Therapeutics compete for the same computational biologists, genome engineers, and investors, though they focus primarily on human medicine. Benchling supplies digital R&D infrastructure and CRISPR-design tools across the life-sciences ecosystem, while Illumina and Bio-Rad provide sequencing and research instrumentation.

These companies are unlikely to launch de-extinction programs directly, but advances in editors, delivery systems, or whole-genome synthesis could reduce the differentiation of Colossal's workflows. A well-capitalized editing platform could later license technology directly to governments, zoos, or agricultural companies, bypassing Colossal's integrated model.

Habitat protection, captive breeding, predator control, and conventional reintroduction compete for the same outcome, species recovery, without the technical uncertainty of de-extinction. Organizations such as Rewilding Europe and established zoo networks can restore ecological functions using living species.

If donors and governments evaluate programs by population recovery per dollar rather than technological spillover, conventional conservation could offer lower costs and faster deployment than Colossal's approach.

Colossal Biosciences is expanding from de-extinction into species engineering and conservation infrastructure, with each program generating capabilities applicable to living wildlife, agriculture, and human health.

The nearer-term opportunity is using de-extinction techniques to prevent extinction in living populations. Methods developed for the dire wolf are being applied to critically endangered red wolves, while work from the thylacine program is being directed toward Tasmanian devils and cane-toad-resistant northern quolls. Bluebuck reproductive tools also extend to threatened antelope species.

These applications could generate services and IP sold to governments, zoos, breeding programs, and conservation NGOs. Wildlife disease projects, such as the oral vaccine program for devil facial tumour disease, move Colossal into veterinary pharmaceuticals, where outcomes can be measured sooner than with full de-extinction. UNEP estimates that annual investment in nature-based solutions must rise to approximately $571 billion by 2030, creating demand for conservation technologies.

BioVault expands Colossal into long-duration biological preservation and genomic data infrastructure. The Dubai facility targets 10,000 species, while the U.S. Fish and Wildlife Service partnership aims to biobank every ESA-listed species. Potential services include sample collection, cell-line creation, cryopreservation, redundant storage networks, and cloud-based cataloging.

Colossal has committed to making endangered-species genomic data freely available, limiting direct data-access monetization. An open-core model could instead generate revenue from sample processing, sequencing, and species recovery. The network becomes harder to replicate as it accumulates rare samples, longitudinal metadata, permits, and preservation expertise.

Colossal has converted internal tools into independent businesses through Form Bio in computational biology and Breaking in plastic-degrading enzymes. Future spinouts could focus on artificial gestation, wildlife vaccines, agricultural gene drives, or reproductive technology for non-model species.

The proposed gene drive against the New World screwworm extends Colossal into agricultural biosecurity and pest control, tying its gene-editing expertise to avoided losses for livestock producers and national biosecurity agencies. Other capabilities, including multiplex genome editing, induced pluripotent stem cells, artificial gestation, and genotype-to-phenotype prediction, could apply to human biotechnology, following companies such as Moderna, Strand Therapeutics, and Bolt Threads that have extended genetic engineering into medicine, agriculture, and materials.

Scientific credibility gap: Colossal's commercial narrative depends on claims that species have been brought back, but scientific standards favor the narrower term "proxy," and the dire-wolf announcement drew criticism from the IUCN Canid Specialist Group and independent scientists who argued that editing a limited number of gray-wolf genes did not recreate an animal that differs from gray wolves across thousands of genes, creating tension between its marketing language and peer-reviewed validation that could erode trust among regulators, specimen custodians, and conservation partners.

Capital-model mismatch: Colossal carries a valuation above $10 billion, while its programs require long, uncertain scientific and regulatory timelines and the company was only beginning to generate revenue in 2026, meaning that if ViaGen, government contracts, licensing, and spinouts do not create material cash flow before investor interest weakens, Colossal may be forced to prioritize media-friendly milestones over the expensive conservation work associated with its brand.

Ecological and regulatory barriers: Producing an engineered animal is easier than establishing a healthy, behaviorally competent, and genetically diverse population in an ecosystem that may have changed since the original species disappeared, while environmental deployment would add FDA oversight of intentional genomic alterations, endangered-species handling rules, international genetic-resource access laws, Indigenous sovereignty considerations, and the IUCN's first global policy on synthetic biology and conservation, adopted in October 2025, any of which could delay or prevent field releases indefinitely.